Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.33%43.750.9%$1519.99m
JNJJohnson & Johnson -1.52%162.240.7%$972.90m
ABBVAbbVie, Inc. -1.97%105.611.9%$972.17m
MRKMerck & Co., Inc. -0.30%71.470.7%$794.72m
LLYEli Lilly & Co. -0.47%229.011.1%$591.74m
BMYBristol-Myers Squibb Co. -1.68%60.281.0%$542.97m
AZNAstraZeneca Plc 4.38%58.001.0%$272.53m
NVSNovartis AG -1.69%82.070.2%$166.16m
SNYSanofi -1.43%47.690.2%$135.73m
GSKGlaxoSmithKline Plc -0.75%38.640.2%$121.96m
RPRXRoyalty Pharma Plc -4.97%36.590.1%$113.18m
NVONovo Nordisk A/S -2.26%99.120.1%$106.86m
VTRSViatris, Inc. -2.69%13.210.0%$106.32m
RGENRepligen Corp. -0.97%303.936.8%$101.98m
APLSApellis Pharmaceuticals, Inc. -4.01%32.840.0%$93.05m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.